"Today marks another great milestone in our partnership with the JDRF in collaboration with the Helmsley Charitable Trust to advance CGM technology for the artificial pancreas, which began several years ago with the JDRF CGM studies and continues through multiple artificial pancreas studies today," said Katie Szyman, President of the Diabetes business of Medtronic. "We are also excited to unveil the optical based glucose sensing technology we acquired several years ago. Advancing sensor accuracy and reliability is core to both organizations' missions to enable people with diabetes to live longer, healthier lives."
CGM devices provide both a real-time snapshot of the glucose level of a person with diabetes, as well as trend information on whether glucose is moving upwards or downwards, and how fast. The devices also provide warnings when the glucose is becoming too high or too low. JDRF's landmark CGM trials have shown that using CGM can significantly improve diabetes control and decrease the frequency of high and low blood sugars when used regularly. Today, these sensors are being used as part of artificial pancreas systems, ones that will reduce the amount of high and low blood sugar people with diabetes experience by automating insulin delivery some of the time. In the future, artificial pancreas systems that restore non-diabetes like glucose levels and are automated most of the time will require advanced sensors with increased accuracy and error detection capabilities. Medtronic has been a pioneer in artificial pancreas systems and developed the first closed loop product, Paradigm Veo, that automatically suspends insulin delivery if the sensor glucose value is equal to or below the low threshold value. This system is commercially available outside of the United States and Medtronic is conducting a pivotal trial to obtain Food and Drug Administration (FDA) approval.
About Type 1 Diabetes (T1D)
T1D is an autoimmune disease in which the body's pancreas stops producing enough insulin, a hormone needed to turn food into energy. People with T1D must test their blood glucose levels, by pricking their fingers for blood or with the aid of a CGM, and administer insulin accordingly via shots or an insulin pump, multiple times throughout every day.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV